Four-and-a-half LIM-only protein 2 (FHL2) is an important mediator in many signaling pathways. In this study, we analyzed the functions of FHL2 in nuclear factor B (NF-B) signaling in the liver. We show that FHL2 enhanced tumor necrosis factor (TNF) receptor-associated factor 6 (TRAF6) activity in transcriptional activation of NF-B targets by stabilizing the protein.
F
our-and-a-half LIM-only protein 2 (FHL2) plays important roles in cell proliferation, apoptosis, and transformation (1) . Endowed with a unique structure exclusively composed of 4.5 LIM domains for protein-protein interaction, FHL2 has been shown to interact with more than 50 cellular partners involved in almost all major signaling pathways that govern essential cellular processes. In hormone signaling, FHL2 is the transcriptional coactivator of both androgen and estrogen receptors (2, 3) . In the transforming growth factor ␤ (TGF-␤) pathway, FHL2 interacts with Smad proteins (4), the transcription repressor Ski (5) , and the E3 ligase Arkadia (6) and plays the role of the positive regulator in response to TGF-␤ signaling. FHL2 is a serum-inducible coactivator of the transcription factor AP1 (7), the downstream effector of receptor tyrosine kinase-initiated signaling cascades. In Wnt/␤-catenin signaling, FHL2 exerts both transcription corepressor and coactivator functions of ␤-catenin, depending on the cellular context (8) (9) (10) (11) . The main receptor of Sonic hedgehog Patched recruits a proapoptotic complex containing FHL2 and caspase 9 and triggers cell death through a caspase 9-dependent mechanism (12) . In the Toll-like receptor (TLR)/tumor necrosis factor (TNF) signaling, FHL2 interacts with TNF receptor-associated factor 2 (TRAF2), TRAF4, and TRAF6 (13) , which are key mediators in the signal transduction mechanisms that activate the nuclear factor B (NF-B) signaling pathway.
NF-B transcription factors are master regulators of immunity, inflammation, cell survival, and proliferation (14) . In steadystate conditions, NF-B is inactive in the cytoplasm through association with the inhibitor of B (IB) proteins. Upon induction by signals ranging from proinflammatory cytokines to cell stress to pathogen-associated molecular patterns, IB proteins undergo phosphorylation, ubiquitination, and degradation, releasing NF-B for translocation to the nucleus, where NF-B family members form homodimers or heterodimers to bind specific DNA sequences and promote transcription of target genes encoding cytokines, chemokines, and survival and growth factors (15) .
The relationship between FHL2 and NF-B is highly cell context dependent. During osteoclast formation stimulated by the receptor activator of NF-B (RANK) ligand, FHL2 inhibits TRAF6-induced NF-B activity (13) . In muscle cells, FHL2 enhances production of interleukin 6 (IL-6) through activation of NF-B and p38 signaling pathways (16) . In HEK293 cells, FHL2 induces TRAF2-mediated activation of NF-B by counteracting the suppressive effects of Tucan/Cardinal on NF-B (17) . The NF-B signaling pathway is crucial for liver biology and disease (18) . Knockout of the RelA/p65 component of NF-B, IB kinase ␤ (IKK␤), or IKK␥ in mice results in embryonic lethality due to liver apoptosis (19, 20) . Deregulation of NF-B signaling through conditional deletion of IKK␤ or IKK␥ or expression of a nondegradable form of IB␣ in the liver leads to either enhancement or inhibition of the development of hepatocellular carcinoma (HCC) (21) (22) (23) .
We have recently reported that enhanced expression of FHL2 in hepatocytes increases both cell proliferation and apoptosis and promotes liver tumorigenesis associated with activation of the Wnt/␤-catenin signaling (24) . Given the crucial functions of NF-B in innate immunity and inflammation, we hypothesized that FHL2 might also have a role in liver hepatic immune cells through its implication in NF-B signaling. Here, we used constitutive FHL2 knockout mice to investigate the relationship between FHL2 and NF-B signaling in liver regeneration and carcinogenesis. We report that deletion of FHL2 suppresses in vitro and in vivo an array of NF-B-mediated effects, including cytokine expression, hepatocyte proliferation, and chemical carcinogeninduced HCC. The underlying mechanisms involve regulation of TRAF6 expression by FHL2. Our findings provide evidence of the requirement of FHL2 for activation of NF-B signaling in the liver.
MATERIALS AND METHODS

Animals. FHL2
Ϫ/Ϫ mice on the Black Swiss-129-SV/J background (25) were backcrossed into C57BL/6J mice over more than eight generations. For partial hepatectomy, F1 FHL2 Ϫ/Ϫ and FHL2 ϩ/ϩ littermates generated by intercrossing FHL2 Ϫ/ϩ mice were used. For diethylnitrosamine (DEN)-induced tumorigenesis, F2 mice were used. F2 FHL2 Ϫ/Ϫ mice were generated by intercrossing F1 FHL2 Ϫ/Ϫ littermates. F2 wild-type (wt) mice were generated by intercrossing F1 FHL2 ϩ/ϩ littermates. All experiments were performed with age-and sex-matched animals. Wildtype and FHL2 Ϫ/Ϫ animals were housed in the same room in a pathogenfree environment at the Institut Pasteur animal facility and received humane care according to the criteria outlined in the Guide for the Care and Use of Laboratory Animals. Experimental procedures were carried out in accordance with French government regulations.
Surgical procedures and treatments. Animal experiments were carried out according to the European Union directives for animal experimentation (decree 2001-131 published in the Journal Officiel 6 February 2001). Two-thirds hepatectomy was performed on adult male mice (8 to 12 weeks old) as described previously (26) . Four to eight animals of each genotype were sacrificed at each time point posthepatectomy. To analyze hepatocyte proliferation, animals were injected intraperitoneally with bromodeoxyuridine (BrdU; 50 mg/kg of mouse body weight) 2 h before livers were harvested. After removal of the liver, part of the remnant liver lobes was fixed immediately in paraformaldehyde (PFA) and stained for BrdU. BrdU-positive cell nuclei were counted on 5 consecutive highpower fields in three animals of each genotype. Others were frozen in nitrogen and stored at Ϫ80°C. For cytokine assay on liver homogenates, livers removed from mice 1 h after partial hepatectomy (PH) were weighed and then homogenized with glass beads in 1 ml phosphate-buffered saline (PBS) using the Mixer Mill MM301 (Retsch). After centrifugation, supernatants were collected for TNF and IL-6 measurement by enzyme-linked immunosorbent assay (ELISA Immunohistochemistry and apoptosis detection. Immunohistochemistry (IHC) was described previously (24) . Primary antibodies include BrdU (Dako), Ki-67 (Novocastra), and F4/80 (BM8) (Santa Cruz Biotechnology) (dilution, 1:100). Sections were probed with secondary antibodies using the Impress kit (Vector Laboratories). Revelation was performed using the 3,3=-diaminobenzidine (DAB) substrate detection kit (Vector Laboratories). Slides were counterstained with Mayer's hematoxylin solution.
Apoptosis was detected by terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling (TUNEL). TUNEL-positive cells were counted on 6 to 10 consecutive high-power fields in three animals of each genotype.
Cell culture, reagents, and reporter assay. 293T, 293-hTLR4/MD2-CD14 (InvivoGen), HEK293 cell lines expressing TLR4/MD2-CD14 and mouse embryonic fibroblasts (MEF) (27) were cultured in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum (FBS). HepG2 cells were cultured in DMEM-F-12 with 3.5 ϫ 10 Ϫ7 M hydrocortisone and insulin (5 g/ml). For reporter assays, 3 ϫ 10 5 cells were plated in six-well plates and transfected using Lipofectamine 2000 (Invitrogen) with expression vectors coding for FHL2, TRAF6, or TRAF6 mutant C70A, Rel/p65, and luciferase reporter containing wt or mutated NF-Bresponsive elements. Luciferase activity was determined 48 h later. A renilla plasmid under the control of thymidine kinase was used as the internal control, and the total DNA amount in each transfection was kept constant by adding an empty vector. All experiments were performed in duplicate and repeated at least three times. FHL2 expression in 293-hTLR4/MD2-CD14 cells and TRAF6 expression in 293T cells were inhibited by lentiviral transduction of FHL2 or TRAF6 short hairpin RNA (shRNA) (Santa Cruz Biotechnology), respectively, followed by selection with puromycin. Lipopolysaccharide (LPS) TLRgrade (ALX-581-012-L002; Alexis Biochemicals) (1 g/ml) was used to stimulate FHL2-knockdown and control 293-hTLR4/MD2-CD14 cells for 18 h.
Protein analysis. Livers were homogenized in lysis buffer containing 50 mM Tris-HCl (pH 8), 200 mM NaCl, 0.1 mM EDTA, 0.5% NP-40, 10% glycerol, and protease inhibitors. For nuclear extraction, MEFs were lysed in 10 mM HEPES (pH 7.8), 10 mM KCl, 1.5 mM MgCl 2 , 1 mM dithiothreitol (DTT), 10% NP-40, and protease inhibitors. After centrifugation, the pellet was resuspended in 400 mM KCl, 50 mM Tris (pH 8), 0.5% NP-40, 1 mM DTT, and protease inhibitors and incubated for 45 min. The nuclear membrane was eliminated by centrifugation. After quantification with Bradford protein assay, equal amounts of protein extract were analyzed by immunoblotting. 293T cells transfected or not with FHL2 were lysed in Laemmli buffer, and protein extracts were resolved in 4 to 12% polyacrylamide gels (Invitrogen) and transferred to Hybond-C extra (Amersham Pharmacia Biotech). Primary antibodies include TRAF6, STAT3, phospho-STAT3, phospho-p65 (S536) (Cell Signaling), p65, PCNA, cyclin-dependent kinase 2 (CDK2), CDK4, and cyclin A (Santa Cruz Biotechnology), FHL2 (MBL), and actin and tubulin (Sigma-Aldrich). Signal intensities of nuclear p65 were scanned and quantified by using the LI-COR/Odyssey infrared image system. To determine TRAF6 turnover, 293T cells were treated with 100 g/ml cycloheximide (SigmaAldrich) and harvested at the indicated times. Signal intensities were scanned and quantified by using NIH ImageJ software as described previously (28) .
Cytokine assay. Bone marrow-derived macrophages (BMDMs) were prepared from wt and FHL2 Ϫ/Ϫ mice as described previously (29) and stimulated for differentiation with 400 u/ml macrophage colony-stimulating factor (M-CSF). A total of 1 ϫ 10 6 adherent BMDMs plated in six-well plates were cultured in RPMI with 10% heat-inactivated FBS and then induced with 1 g/ml LPS for 24 h. TNF and IL-6 were measured in supernatants with ELISA as specified by the manufacturer (DuoSet, R&D Systems, Minneapolis, MN).
Kupffer cells were isolated from animals on MCD or normal diets as described previously (30) . TNF and IL-6 were measured in supernatants with ELISA.
RNA analysis. Total RNA was extracted from Kupffer cells or homogenized liver tissues using TRIzol (Invitrogen). RNA (1 g) was reverse transcribed using random primers (Promega) and RevertAid HMinus reverse transcriptase (Fermentas). The relative levels of mRNAs were determined by real-time PCR using fast-start universal SYBR green (Roche). The mean copy number of each gene from a triplicate determination was normalized to the mean copy number of hypoxanthine-guanine phosphoribosyltransferase (HPRT). The following primers were used for realtime PCR: FHL2, 5=-GTCCTACAAGGATCGGCACT-3=, 5=-ACAGGTG AAGCAGGTCTCGT-3=; HPRT, 5=-ATGCCGAGGATTTGGAAAAA-3=, 5=-ACAATGTGATGGCCTCCCA-3=; TLR4, 5=-AACAAGAAACGGCAA CTTGGA-3=, 5=-CCATAGCAGAGCCCCAGGT-3=; IL-6, 5=-TTGCCTT CTTGGGACTGATGCT-3=, 5=-GTATCTCTCTGAAGGACTCTGG-3=; TNF, 5=-GTGACCTGGACTGTGGGCCTC-3=, 5=-GGCTCTGTGAGGA AGGCTGTG-3=.
Statistical analysis. A chi-square test was used for statistical analysis of tumor incidence. Student's t test was used for other statistical analysis. The significant level was defined as P values of Ͻ0.05.
Tumor induction and analysis. Fourteen-day-old mice were injected intraperitoneally with 25 mg/kg DEN (Sigma) and sacrificed 3 h, 6 h, 15 h, 24 h, 48 h, or 8 months later. Livers were removed for RNA, protein, IHC, and TUNEL analyses.
Blood analysis. Blood samples were collected from mice, followed by centrifugation. Insulin, glucose, aspartate aminotransferase (ASAT), and triglyceride were measured in plasma by Vebiotel Laboratory (Arcueil, Val de Marne, France). A total of 30 l of whole-blood samples was used for counting cell numbers with a vet ABC automat.
RESULTS
FHL2
؊/؊ mice exhibit diminished regeneration response after partial hepatectomy. A previous study showed that overexpression of FHL2 in hepatocytes accelerated liver regeneration (24) . To further investigate the role of FHL2 in liver regeneration, we performed a partial hepatectomy (PH) on FHL2 Ϫ/Ϫ mice and sacrificed the mice at different time points to examine hepatocyte proliferation. BrdU incorporation demonstrated lower levels in DNA synthesis at 24 h and 48 h after PH in FHL2 Ϫ/Ϫ mice than in wt mice but similar levels in DNA synthesis at 72 h and 96 h after PH between wt and FHL2 Ϫ/Ϫ mice ( Fig. 1A and B and data not shown). TUNEL analysis revealed no significant difference of apoptosis in regenerating livers from FHL2 Ϫ/Ϫ and wt animals (Fig. 1C) . While cell cycle regulators cyclin D1, cyclin A, CDK2, CDK4, and PCNA were not significantly different between wt and FHL2 Ϫ/Ϫ regenerating livers, the levels of NF-B p65 phosphorylation at S536, indicative of NF-B activation, were lower in FHL2 Ϫ/Ϫ livers at 24 h and 48 h after PH (Fig. 1D) . FHL2 Ϫ/Ϫ mice eventually restored the same liver weight as wt mice 8 days after PH. These results showed that liver regeneration was delayed in FHL2 Ϫ/Ϫ mice after PH. TNF and IL-6 are major cytokines for priming normally quiescent hepatocytes to enter the cell cycle in response to hepatic injury (31, 32) . Examination of cytokine production 1 h after operation showed that TNF and IL-6 were expressed at dramatically lower levels in regenerating livers of FHL2 Ϫ/Ϫ mice than those of wt mice (Fig. 1E ). IL-6 stimulates compensatory hepatocyte proliferation through activation of the signal transducer and activator of transcription 3 (STAT3). Accordingly, immunoblotting analysis revealed reduced phosphorylation of STAT3 in FHL2 Ϫ/Ϫ livers compared to wt counterparts at 1 h after PH (Fig. 1F) . Overall, these findings suggest that loss of FHL2 impairs cytokine production and affects cytokine-regulated early proliferative response to hepatic injury.
Histological analysis of the FHL2-deficient liver revealed no notable anomaly ( Fig. 2A ) and no HCC after 2 years of observation. FHL2
Ϫ/Ϫ mice show no spontaneous liver dysfunction, as attested by the absence of significant alterations in serum insulin, glucose, aspartate aminotransferase (ASAT), and triglyceride (Fig.  3A) . Kupffer cells are the major cytokine producer in the liver. F4/80 immunostaining showed morphology and percentage of Kupffer cells similar to parenchymal cells between wt and FHL2 Ϫ/Ϫ livers ( Fig. 2B and C) . Analysis by real-time PCR on RNA from Kupffer cells isolated from wt mice confirmed expression of FHL2 in this specific cell type (Fig. 2D) . In addition, no difference was observed in cell composition in peripheral blood between wt and FHL2 Ϫ/Ϫ mice (Fig. 3B) . To assess the impact of FHL2 deficiency on cytokine production by Kupffer cells, we fed wt and FHL2 Ϫ/Ϫ animals an MCD, which is known to induce steatosis-associated inflammation (33, 34) . Kupffer cells isolated from animals on an MCD or control mice were cultured in vitro, and TNF and IL-6 in the supernatant were measured by ELISA. Remarkably, even though TNF and IL-6 were elevated in both wt and FHL2 Ϫ/Ϫ Kupffer cells from animals on an MCD, their levels were significantly lower in FHL2 Ϫ/Ϫ cells (Fig. 2E ). Taken together, these results suggest that deficiency of FHL2 may affect signaling pathways that control cytokine expression.
FHL2 deficiency decreases LPS-induced cytokine production in macrophages. NF-B signaling plays a central role in initiation of liver regeneration, as it promotes production of TNF and IL-6 (31). Lipopolysaccharide (LPS) is one of the important molecules for activation of NF-B after PH (35) , because liver injury provokes an increase of LPS levels originating from commensal intestinal bacteria. To examine the role of FHL2 in NF-B activation induced by LPS, we knocked down FHL2 in 293-hTLR4/MD2-CD14 cells (Fig. 4A) , which express the hTLR4/MD2-CD14 receptor complex for LPS, and transfected it with the NF-B wt reporter or a reporter mutated at the NF-B responsive element, followed by stimulation with LPS. While LPS potently activated NF-B reporter in control cells, knockdown of FHL2 reduced the LPSmediated NF-B reporter activation by half (Fig. 4B) . No effect of LPS was observed on the mutated NF-B responsive elements (Fig. 4B) . NF-B regulates transcriptional programs that induce genes coding for cytokines, including TNF and IL-6. To assess the effects of FHL2 on NF-B-mediated cytokine production, bone marrow-derived macrophages isolated from wt and FHL2 Ϫ/Ϫ mice were stimulated for differentiation with M-CSF, followed by treatment with LPS. TNF and IL-6 in the supernatant were measured by ELISA. Significant reduction of TNF and IL-6 was observed in FHL2 Ϫ/Ϫ macrophages after LPS stimulation (Fig. 4C) , even though similar expression levels of TLR4 were detected in FHL2 Ϫ/Ϫ and wt cells (Fig. 4D) . To exclude the possibility that mice lacking FHL2 may harbor pathogens that elicit immune tolerance to LPS, we tested sera from wt or FHL2 Ϫ/Ϫ mice in the TLR4 reporter cell line for screening LPS, which can be recognized by TLR4. None of the sera elicited any response in the line (data not shown). Taken together, these findings show that FHL2 might be required for triggering NF-B-mediated cytokine production. FHL2 participates in NF-B signaling through TRAF6. FHL2 interacts with both cytoplasmic and nuclear proteins and is a cofactor of many transcription factors. We next examined whether FHL2 could synergize with NF-B transcription factor in regulation of transcription by coexpressing FHL2 and p65 in the hepatoma cell line HepG2. FHL2 effectively potentiated p65 activity (Fig. 5A) . However, we did not detect interaction between FHL2 and p65. We thus tested if FHL2 had impacts on NF-B translocation. Wild-type or FHL2 Ϫ/Ϫ mouse embryonic fibroblasts (MEF) were stimulated with LPS, and nuclear p65 expression was analyzed by immunoblotting. Deletion of FHL2 delayed nuclear translocation of NF-B (Fig. 5B and C) , suggesting that the effect of FHL2 on NF-B is achieved mainly in the cytoplasm. It has been reported that FHL2 interacts with TRAF6 (13), an E3 ubiquitin ligase essential for the activation of NF-B. To investigate the cooperation of FHL2 with TRAF6, we transfected the NF-B luciferase reporter in combination with FHL2 and TRAF6 in 293T cells. Overexpression of wt TRAF6, but not the C70A mutant lacking E3 activity, readily activated NF-B-dependent transcription (Fig. 5D, lanes 5 and 9) , in agreement with previous reports (33) (34) (35) . Strikingly, whereas FHL2 alone had a barely detectable effect on NF-B reporter activity (Fig. 5D, lanes 2 to 4) , it cooperated with wt TRAF6 but not the C70A mutant to enhance NF-B signaling in a dose-dependent manner (Fig. 5D, lanes 6 to 8 and 10) . Next, we knocked down TRAF6 in 293T cells and carried out NF-B luciferase reporter assay in these cells. The activity of FHL2 on the NF-B reporter was significantly diminished in TRAF6-knocked-down cells (Fig. 5E ), indicating that TRAF6 is required for FHL2 to fully exert its function in activation of NF-B signaling. To elucidate the mechanisms of FHL2 and TRAF6 coopera-tion, we assessed the impact of FHL2 on the stability of endogenous TRAF6 by transfecting FHL2 in 293T cells, followed by blocking protein synthesis with cycloheximide. Overexpression of FHL2 resulted in an increase in the stability of endogenous TRAF6 ( Fig. 5F and G) . These findings suggest that FHL2 participates in NF-B signaling most likely via its ability to interact with the pathway component TRAF6.
Loss of FHL2 reduces susceptibility to DEN-induced liver carcinogenesis. NF-B activation is intimately linked to hepatocarcinogenesis (36) . A previous report demonstrated that hepatocyte-specific depletion of IKK␤ increased carcinogenesis induced by the hepatic carcinogen diethylnitrosamine (DEN), whereas deletion of IKK␤ in both hepatocytes and nonparenchymal cells reduced DEN-induced tumorigenesis (21) . It has been argued that inactivation of NF-B through deletion of IKK␤ diminished induction of hepatomitogens in hepatic hematopoietic-derived cells, resulting in reduced compensatory proliferation of hepatocytes and thus tumorigenesis (21) . As FHL2 Ϫ/Ϫ mice exhibited diminished cytokine production in response to hepatic injury, we asked whether constitutive deletion of FHL2 might have similar effects as IKK␤ deletion on carcinogenesis. To address it, we used the DEN model for liver carcinogenesis by injecting the chemical carcinogen into 14-day-old wt and FHL2 Ϫ/Ϫ mice. As expected for wt mice, all males (8/8) developed HCCs within 8 months, versus 45.4% females with HCCs (5/11) (Table 1) . Interestingly, tumor incidence was significantly lower in both FHL2 Ϫ/Ϫ males (P Ͻ 0.0005) and females (P Ͻ 0.005) than in wt mice, as only 71.4% male (10/14) and 18.7% female (3/16) animals deficient for FHL2 developed tumors (Table 1) . Histopathological analysis revealed HCCs of various sizes, most often multifocal and randomly distributed in the liver parenchyma in both wt and FHL2 Ϫ/Ϫ mice ( Fig. 6A to F ). Tumors were well demarcated but not encapsulated, focally invading the remaining parenchyma ( Fig. 6C and D) . Tumor cells were mostly organized in nests and trabeculae, rarely in tubules, with lipids in the cytoplasm and giant nucleoli (Fig. 6E  and F) . Anisocytosis, anisokaryosis, and cellular atypia were frequent (data not shown). No vascular invasion was observed. Although not significant, FHL2 expression was enhanced in tumor tissues from wt mice (Fig. 6G) . These data indicate that loss of FHL2 decreases susceptibility to DEN-induced hepatocarcinogenesis.
DEN-induced HCC requires NF-B-dependent production of IL-6 by Kupffer cells and the activation of STAT3 by IL-6 in hepatocytes (37, 38) . We compared early effects of DEN on IL-6 and TNF expression in wt and FHL2 Ϫ/Ϫ livers and observed a trend but not a significant decrease of IL-6 in FHL2 Ϫ/Ϫ mice at the 3-h time point (Fig. 7A) . FHL2 expression was not enhanced by DEN administration in wt mice (Fig. 7A) . Analysis of STAT3 activation by immunoblotting revealed delayed and reduced phosphorylation of STAT3 in FHL2 Ϫ/Ϫ mice (Fig. 7B) , suggesting that FHL2 deficiency affects the IL-6/STAT3 axis in the DEN model. Ki-67 immunostaining demonstrated a lower number of proliferating hepatocytes in FHL2 Ϫ/Ϫ mice than wt mice 24 h and 48 h after DEN exposure (Fig. 7C and D) . Moreover, FHL2
Ϫ/Ϫ mice exhib- ited lower levels of cell death at the 6-h time point (Fig. 7E and F) . Taken together, loss of FHL2 diminishes STAT3 activation, hepatocyte proliferation, and apoptosis, which may account for the reduced susceptibility of FHL2 Ϫ/Ϫ mice to DEN-induced hepatocarcinogenesis.
DISCUSSION
FHL2 has been shown to inhibit NF-B activity in osteoclastogenesis (13) . However, increasing evidence suggests that FHL2 has a dual role of both activating and suppressing NF-B signaling in a cell context-dependent fashion (16, 17) . Our results show that FHL2 acts as a positive regulator of NF-B signaling in the liver at early phases of proliferative response and in chemical carcinogeninduced DNA damage in vivo. Loss of FHL2 produces inhibitory effects on liver regeneration by attenuating the activation of NF-B in hematopoietic-derived cells during the initial stages of hepatic injury. Liver injury increases the levels of LPS originating from commensal intestinal bacteria in the portal circulation (35) . The attenuated initial phase of inflammatory signaling in FHL2 Ϫ/Ϫ livers after partial hepatectomy correlates with reduced production of inflammatory cytokines by FHL2 Ϫ/Ϫ macrophages in response to LPS in vitro, suggesting that the hyporesponsiveness of FHL2 Ϫ/Ϫ mice to hepatic injury might be mediated by suppression of TLR-induced NF-B activity. However, this inhibitory effect is apparently insufficient to effectively restrain liver weight restoration, possibly because there exist redundant mechanisms that may functionally compensate for FHL2 deficiency. These findings underline the importance of the homeostatic functions of FHL2 in controlling NF-B signaling for the regulation of cytokine production and hepatocyte proliferation.
Although the molecular mechanisms governing FHL2 involvement in NF-B signaling are still unfolding, it is likely that the effects of FHL2 deficiency are operated, at least partly, by the suppression of TRAF6 activity. Activation of NF-B signaling by TRAF6 requires polyubiquitination of TRAF6 through lysine 63 (K63) (39) , which initiates phosphorylation and ubiquitination cascades in the downstream effectors, including TAK1, IB, and IKK␥ (40) . The activity of these downstream effectors might be regulated by the interaction of FHL2 with TRAF6 and subsequent stabilization of TRAF6 by FHL2, which are needed for full transmission of signals that activate NF-B, as abrogation of FHL2 delayed NF-B nuclear translocation. FHL2 is known to interact with several RING domain E3s. Recently, we have shown that FHL2 inhibits assembly of ubiquitin chains K27 and K63 on the E3 ligase Arkadia, a regulator of TGF-␤ signaling (41) . In the case of TRAF6, we did not observe any change of ubiquitination patterns provoked by FHL2 (data not shown). Further studies are required for elucidating the regulatory mechanisms. Functional specificity of FHL2 and TRAF6 cooperation in the balance between activation and inhibition of NF-B signaling depending on environmental cues, such as osteoclastogenesis stimulated by RANK ligand, may explain the context-dependent and seemingly paradoxical effects of FHL2 on NF-B signaling that have been reported (13) . Interestingly, FHL2 is also a target of TRAF6 (42) , which adds another layer of complexity in biological output of FHL2 relating to TRAF6.
In addition to the well-established role of FHL2 in both proliferation and apoptosis (27, 43) , FHL2 is also associated with oncogenesis and cancer malignancies (24, 44) . Loss of FHL2 displays inhibitory effects on liver carcinogenesis almost as effective as deletion of IKK␤ in suppressing DEN-induced tumorigenesis. A previous report has demonstrated that hepatocyte proliferation in 
